Skip to main content

Table 3 The relationship between CTCs enumeration and TNM stage of NPC patients

From: Circulating tumor cells with karyotyping as a novel biomarker for diagnosis and treatment of nasopharyngeal carcinoma

  Newly diagnosis (M0, N = 29) Relapse/Distant metastasis after treatment (N = 21)
Stagea Nb No. of CTCs Nb No. of CTCs
Range Mean ± SD Range Mean ± SD
Total 29 0–24 3.7 ± 4.6 21 0–45 8.6 ± 13.3
T-classification
 T1 5 1–3 2.0 ± 1.0 2 1–4 2.5 ± 2.1
 T2 5 0–13 3.8 ± 5.3 3 1–8 3.3 ± 4.0
 T3 7 0–7 3.0 ± 2.2 6 0–22 3.0 ± 3.0
 T4 12 1–24 4.8 ± 6.2 10 0–45 12.1 ± 17.9
N-classification
 N0 3 0–5 3.0 ± 2.6 1 16 16.0
 N1 1 1 1.0 7 1–45 16.4 ± 19.8
 N2 20 0–24 4.4 ± 5.4 9 0–8 2.6 ± 2.6
 N3 5 1–3 2.0 ± 0.7 4 1–22 6.8 ± 10.1
TNM stage
 I 0 0
 II 2 0–1 0.5 ± 0.7 2 1–4 2.5 ± 2.1
 III 12 0–13 3.7 ± 3.4 7 0–12 8.6 ± 13.3
 IV 15 1–24 4.1 ± 5.7 12 0–45 12.0 ± 16.8
  1. Detectable CTCs were existence in 27 newly diagnosed (M0) patients and 19
  2. relapsed/distant metastatic patients. Data were presented as mean ± standard deviation
  3. a Stage for patients with relapse/distant metastasis after treatment refered to TNM stage at NPC initial diagnosis
  4. b N referred to number of patients